Literature DB >> 2021425

New developments in the pre- and post-exposure treatment of rabies.

B Dietzschold1, H C Ertl.   

Abstract

Two approaches have been made to develop the alleged "second generation rabies vaccines". One utilizes recombinant DNA, expressing the G protein gene in a heterotypic host, the vaccinia virus, and has proven efficacious in protecting animals from rabies infection. The second approach posits that only a portion of the native viral antigen may be required to induce protective response. To define regions of the subunit molecule recognized by different immune effectors, epitopes on the G protein and nucleoprotein were identified which are recognized by B and T cells. These epitopes were delineated using chemically or enzymatically cleaved fragments of the native antigens or overlapping synthetic peptides covering the entire antigenic amino acid sequence. Protein fragments or synthetic peptides evincing antigenic activity were tested for ability to induce virus-specific immune responses in vivo. Immunization with synthetic peptides carrying epitopes for B and T cells conferred solid protection against lethal rabies virus infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021425

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  4 in total

1.  Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America.

Authors:  K Morimoto; M Patel; S Corisdeo; D C Hooper; Z F Fu; C E Rupprecht; H Koprowski; B Dietzschold
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

2.  Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1.

Authors:  V Yusibov; A Modelska; K Steplewski; M Agadjanyan; D Weiner; D C Hooper; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 3.  Vaccination of adults against travel-related infectious diseases, and new developments in vaccines.

Authors:  P C Döller
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

4.  Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice.

Authors:  U Steinhoff; U Müller; A Schertler; H Hengartner; M Aguet; R M Zinkernagel
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.